New drug cocktail aims to shrink Hard-to-Treat GI tumors
NCT ID NCT05934331
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a new drug called LM-302 combined with other cancer treatments in people with advanced gastrointestinal cancers that have a specific marker (CLDN18.2). The study aims to see if the combination can slow tumor growth or shrink tumors. About 276 participants will receive different drug combinations, and researchers will monitor how long the cancer stays under control and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LM-302 (an experimental drug) combined with other cancer drugs like toripalimab, capecitabine, or nivolumab
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced gastrointestinal cancers that have not responded to standard therapy.
- What could go wrong
- This is an early-phase trial with only 276 participants, so results may not apply to everyone. The combination therapy may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.